Meissa's cofounder and CEO Marty Moore speaks with Rahul Chaturvedi, host of the Biotech 2050 podcast, and explains why an intranasal vaccine is needed as an end game strategy for the COVID-19 pandemic. He also describes his career and entrepreneurial journey from an associate professor at Emory University to founding Meissa Vaccines to advance a new way to create live attenuated vaccines. With Meissa's vaccines currently in clinical trials for SARS-CoV-2 and RSV, Marty shares how Meissa is taking a global approach to tackle life-threatening respiratory viruses and their drive to protect the patients that need it the most.
top of page
bottom of page
Comments